208 related articles for article (PubMed ID: 17249904)
1. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting.
Bernardo M; Crawford P; Hertel J; Sholer C; Xu X; Goss T; Kewalramani R; Globe D
J Manag Care Pharm; 2006; 12(9):714-25. PubMed ID: 17249904
[TBL] [Abstract][Full Text] [Related]
2. Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.
Reitan JF; van Breda A; Corey-Lisle PK; Shreay S; Cong Z; Legg J
Clin Drug Investig; 2013 May; 33(5):383-9. PubMed ID: 23553358
[TBL] [Abstract][Full Text] [Related]
3. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.
Crémieux PY; Fastenau JM; Kosicki G; Piech CT; Fendrick AM
J Manag Care Pharm; 2004; 10(6):531-7. PubMed ID: 15548125
[TBL] [Abstract][Full Text] [Related]
4. Costs to physician offices of providing medications to medically indigent patients via pharmaceutical manufacturer prescription assistance programs.
Clay P; Vaught E; Glaros A; Mangum S; Hansen D; Lindsey C
J Manag Care Pharm; 2007; 13(6):506-14. PubMed ID: 17672812
[TBL] [Abstract][Full Text] [Related]
5. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.
Gauthier-Loiselle M; Michalopoulos SN; Cloutier M; Serra E; Bungay R; Szabo E; Guérin A
J Manag Care Spec Pharm; 2021 Dec; 27(12):1703-1713. PubMed ID: 34818094
[No Abstract] [Full Text] [Related]
6. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Duh MS; Mody SH; McKenzie RS; Lefebvre P; Gosselin A; Bookhart BK; Piech CT
Drugs Aging; 2006; 23(12):969-76. PubMed ID: 17154661
[TBL] [Abstract][Full Text] [Related]
7. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
Stephens JM; Emerson LC; Spry LA; Caloyeras JP; Anderson ER; Reitan JF; Ashfaq A
Curr Med Res Opin; 2016; 32(2):313-20. PubMed ID: 26583202
[TBL] [Abstract][Full Text] [Related]
8. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
9. Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in U.S. and Canadian Clinical Practice.
Blume SW; Yeomans K; Allen-Ramey F; Smith N; Kim H; Lockey RF; Nichol MB
J Manag Care Spec Pharm; 2015 Nov; 21(11):982-90. PubMed ID: 26521110
[TBL] [Abstract][Full Text] [Related]
10. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
11. Costs of adult vaccination in medical settings and pharmacies: an observational study.
Singhal PK; Zhang D
J Manag Care Spec Pharm; 2014 Sep; 20(9):930-6. PubMed ID: 25166292
[TBL] [Abstract][Full Text] [Related]
12. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
Sikand H; Decter A; Greco T; Watson SH; Kang YJ; Mody SH; Piech CT; Duh MS; Naeem A
Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
[TBL] [Abstract][Full Text] [Related]
13. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
[TBL] [Abstract][Full Text] [Related]
14. Erythropoiesis-Stimulating Agent (ESA) Practice Patterns in Patients With Chemotherapy-Induced Anemia (CIA) Treated at Hospital Oncology Clinics.
Reitan JF; van Breda A; Shreay S; Corey-Lisle PK; Cong Z
Hosp Pharm; 2013 Feb; 48(2):120-6. PubMed ID: 24421449
[TBL] [Abstract][Full Text] [Related]
15. Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries.
De Cock E; Dellanna F; Khellaf K; Klatko W; Maduell F; Raluy-Callado M; Villa G
J Med Econ; 2013; 16(5):648-56. PubMed ID: 23402559
[TBL] [Abstract][Full Text] [Related]
16. Model for optimal space and staff efficiency in an otolaryngology clinic.
Benninger MS; Strode SR
Otolaryngol Head Neck Surg; 1998 Oct; 119(4):394-7. PubMed ID: 9781998
[TBL] [Abstract][Full Text] [Related]
17. Cost and reimbursement of providing routine vaccines in outpatient obstetrician/gynecologist settings.
Dempsey AF; Pyrzanowski J; Campbell J; Brewer S; Sevick C; O'Leary ST
Am J Obstet Gynecol; 2020 Oct; 223(4):562.e1-562.e8. PubMed ID: 32179023
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
